BioWorld

Nov. 25, 2008

Alpharma Rethinks King's Bid, Agrees to be Acquired for $1.6B

Two months after urging shareholders to reject a $37-per-share offer from King Pharmaceuticals Inc., Alpharma Inc. changed its mind and agreed to the merger, which values the specialty pharma firm at about $1.6 billion. (BioWorld Today) Read More

J&J Seeks to Acquire Omrix in $438M Cash Tender Offer

Host Cell Components Promising Broad-Spectrum Antiviral Targets

NewCo News: Compellis Does Obesity Drug Development by the Nose

Another Depomed Deal: $68M Delivery License with Covidien

Naproxcinod Meets Endpoints in Third Phase III Arthritis Trial

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for April 22, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 21, 2026

Psychedelic space expanding on Trump’s EO

BioWorld

Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...

At AACR: Epigenetic fingerprints in metastases track tumor origin

BioWorld

When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...

In the clinic for April 21, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...